Evidence map›Paper›PMID 41204978›Full record

ArticleDiabetologia2025

Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative.

Salla Kuusela, Jaakko J Koskenniemi, Toni Valtanen, Tytti Pokka, Taina Härkönen, Jorma Ilonen, Johanna Lempainen, Anni Kyrönniemi, Jorma Toppari, Mikael Knip and 2 more

Abstract read
In one paragraph

Article in Diabetologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Salla KuuselaDepartment of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0003-4945-3089
Jaakko J KoskenniemiPopulation Health Research Centre, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0002-9348-3325
Toni ValtanenDepartment of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland.
Tytti PokkaDepartment of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0001-5488-5885
Taina HärkönenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-1068-224X
Jorma IlonenInstitute of Biomedicine, Immunogenetics Laboratory, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-9973-2062
Johanna LempainenDepartment of Pediatrics, Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0001-9893-1468
Anni KyrönniemiDepartment of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland.ORCID http://orcid.org/0000-0003-0065-7531
Jorma ToppariPopulation Health Research Centre, University of Turku and Turku University Hospital, Turku, Finland.ORCID http://orcid.org/0000-0003-2228-334X
Mikael KnipResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-0474-0033
Päivi KeskinenDepartment for Children and Adolescents, Tampere University Hospital, Tampere, Finland.
Riitta VeijolaDepartment of Pediatrics, Research Unit of Clinical Medicine, Medical Research Center, University of Oulu, Oulu, Finland. riitta.veijola@oulu.fi.ORCID http://orcid.org/0000-0002-6557-270X

Funding

Centre of Excellence in Molecular Systems Immunology and Physiology Research 2012-2017 250114Diabetestutkimussäätiö 985-531d8Emil Aaltosen Säätiö 6f9f1bEuropean Commission BMH4-CT98-3314Juvenile Diabetes Research Foundation International 1-SRA-2016-342-M-RJuvenile Diabetes Research Foundation International 1-SRA-2019-732-M-BJuvenile Diabetes Research Foundation International 3-SRA-2020-955-S-BJuvenile Diabetes Research Foundation International 3-SRA-2023-1433-S-BResearch Council of Finland 292538
6 · The paper itself

Abstract

aims/hypothesisIslet autoimmunity during presymptomatic type 1 diabetes is heterogeneous. We hypothesised that a positive family history of type 1 diabetes is associated with specific characteristics of the autoimmune process resulting in clinical diabetes. In a prospective birth cohort study, we compared the initiation and evolution of islet autoimmunity and the rate of progression from islet autoimmunity to diabetes between children with and without a first-degree relative (FDR) with type 1 diabetes.

methodsIn the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study, we prospectively followed children with HLA-conferred susceptibility from birth for the appearance of islet autoantibodies (IAA, GADA, IA-2A, ZnT8A), further development of islet autoimmunity, and progression to clinical diabetes. The presence of type 1 diabetes among their FDRs was recorded at the time of birth, and the family history data was updated during the follow-up period.

resultsAmong a total of 1334 children with confirmed positivity for at least one islet autoantibody, 145 (10.9%) had one or more FDRs with type 1 diabetes at the time of birth (FDR+). During a median follow-up period of 8.6 years, FDRs of an additional 87 children developed type 1 diabetes (FDR- FDR+). At seroconversion, both FDR+ and FDR- FDR+ children were significantly more often positive for GADA and multiple autoantibodies than children without affected FDRs (FDR-). The seroconversion age was similar between the three groups (median 2.7 vs 2.1 vs 3.0 years in FDR+, FDR- FDR+ and FDR- children, respectively). During the follow-up period, FDR+ and FDR- FDR+ children more often had IAA, GADA, IA-2A and multiple autoantibodies than FDR- children, and progressed more frequently to diabetes (55.9 vs 57.5 vs 38.9%, respectively). Time from seroconversion to clinical diabetes was significantly shorter in FDR+ children compared with FDR- children (2.7 vs 3.6 years). Children with paternal type 1 diabetes at birth (n=71; i.e., the father had type 1 diabetes) were twice as often positive for multiple autoantibodies at seroconversion as those with maternal type 1 diabetes (n=50; i.e. the mother had type 1 diabetes) (39.4% vs 20.0%). CONCLUSIONS/

interpretationAt seroconversion, genetically susceptible children who had one or more FDRs with type 1 diabetes, especially an affected father, were more often positive for GADA and multiple islet autoantibodies. During the follow-up period, children with an affected FDR were more often positive for IAA, GADA and IA-2A, and progressed to clinical type 1 diabetes more often and faster than children without an affected FDR. These data should be considered when designing intervention and screening studies.

Indexed as

ChildrenFamily historyFirst-degree relativeGenetic riskIslet autoimmunityType 1 diabetes

Identifiers

PMID41204978
PMCPMC12686032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.